Abstract
Lixisenatide is a new GLP-1 receptor agonist administered once daily, with unique pharmacological properties. The pharmacokinetics of lixisenatide, resulting in the maximum effect on glycemia reduction being attained at the time of the postprandial glycemia increase, appears as rather advantageous for treatment in combination with other pharmaceuticls.